Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Commentary|Videos|May 29, 2025
Going for GOLD: Updated COPD Guidelines with Gerard Criner, MD
Author(s)Albert Rizzo, MD, Gerard Criner, MD
Fact checked by: Victoria Johnson
Gerard Criner, MD, spells out GOLD improvements, from interventions like smoking cessation and pulmonary rehabilitation to the heightened importance of spirometry for diagnosis.
Advertisement
Advertisement
Chronic obstructive pulmonary disease (COPD) remains a major public health challenge, affecting over 14 million adults in the U.S.—with many more likely undiagnosed—and ranking as the sixth leading cause of death nationally and fourth globally. As of 2024, more than half of diagnosed U.S. patients are women, with higher prevalence seen in rural areas, and while tobacco smoking accounts for over 70% of COPD cases in high-income countries, household air pollution and occupational exposures drive a significant burden worldwide.
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
Drinking fell for the first time since COVID-19, but not for adults 50 to 64. Hepatologists explain what clinicians can do to close the gap.
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.
Advertisement
Advertisement